← Back to Search

Proflavine Hemisulfate for Colon Polyps

Phase < 1
Waitlist Available
Led By Sharmila Anandasabapathy, MD
Research Sponsored by Anandasabapathy, Sharmila, M.D.
Eligibility Criteria Checklist
Specific guidelines that determine who can or cannot participate in a clinical trial
Must have
Be older than 18 years old
Timeline
Screening 3 weeks
Treatment Varies
Follow Up 1 day
Awards & highlights

Study Summary

The overall objective of this study is to obtain data to evaluate whether high-resolution imaging of the colon can assist clinicians in detecting dysplastic (precancerous) and neoplastic areas. This is a pilot study of a novel technology, a miniaturized microscope device which can be used during standard endoscopy to image the gastrointestinal epithelium. Theoretically, by visualizing superficial mucosal changes at a high-resolution and magnification, the investigators will be able to obtain optical images that can be used to guide endoscopic biopsy and polypectomy. This may foster the selective targeting of dysplasia/neoplasia, thereby improving diagnostic accuracy.

Eligible Conditions
  • Colon Polyps
  • Colonic Dysplasia
  • Anal Intraepithelial Neoplasia

Timeline

Screening ~ 3 weeks
Treatment ~ Varies
Follow Up ~1 day
This trial's timeline: 3 weeks for screening, Varies for treatment, and 1 day for reporting.

Treatment Details

Study Objectives

Outcome measures can provide a clearer picture of what you can expect from a treatment.
Primary outcome measures
to determine whether tissue in nepoplastic or non-neoplastic

Trial Design

1Treatment groups
Experimental Treatment
Group I: Proflavine HemisulfateExperimental Treatment1 Intervention
Treatment
First Studied
Drug Approval Stage
How many patients have taken this drug
Proflavine
FDA approved

Find a Location

Who is running the clinical trial?

Anandasabapathy, Sharmila, M.D.Lead Sponsor
7 Previous Clinical Trials
1,648 Total Patients Enrolled
Sharmila Anandasabapathy, MDPrincipal InvestigatorIcahn School of Medicine at Mount Sinai
5 Previous Clinical Trials
1,674 Total Patients Enrolled
~12 spots leftby Jul 2025